

Thomas Aparicio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1837410/publications.pdf>

Version: 2024-02-01

119
papers

3,069
citations

186265
28
h-index

189892
50
g-index

119
all docs

119
docs citations

119
times ranked

4632
citing authors

#	ARTICLE	IF	CITATIONS
1	Small bowel adenocarcinoma: Epidemiology, risk factors, diagnosis and treatment. Digestive and Liver Disease, 2014, 46, 97-104.	0.9	245
2	Geriatric Factors Predict Chemotherapy Feasibility: Ancillary Results of FFCD 2001-02 Phase III Study in First-Line Chemotherapy for Metastatic Colorectal Cancer in Elderly Patients. Journal of Clinical Oncology, 2013, 31, 1464-1470.	1.6	192
3	Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncology, 2017, 3, 1546.	7.1	154
4	Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment. , 2019, 7, 74.		151
5	Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. Journal of the National Cancer Institute, 2016, 108, djv438.	6.3	127
6	Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOV19). European Journal of Cancer, 2020, 141, 62-81.	2.8	122
7	Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Gut, 2020, 69, 531-539.	12.1	97
8	Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. Critical Reviews in Oncology/Hematology, 2009, 71, 249-257.	4.4	92
9	Nutritional Status Affects Treatment Tolerability and Survival in Metastatic Colorectal Cancer Patients: Results of an AGEO Prospective Multicenter Study. Oncology, 2011, 81, 395-402.	1.9	80
10	ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. European Journal of Cancer, 2014, 50, 1740-1746.	2.8	79
11	Secondâ€line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of firstâ€line platinumâ€based chemotherapy. Cancer, 2011, 117, 1422-1428.	4.1	71
12	Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). Journal of Clinical Oncology, 2018, 36, 674-681.	1.6	70
13	Leptin reduces the development of the initial precancerous lesions induced by azoxymethane in the rat colonic mucosa. Gastroenterology, 2004, 126, 499-510.	1.3	65
14	Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Digestive and Liver Disease, 2018, 50, 15-19.	0.9	60
15	Small bowel adenocarcinoma: Results from a nationwide prospective ARCADâ€NADEGE cohort study of 347 patients. International Journal of Cancer, 2020, 147, 967-977.	5.1	57
16	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). European Journal of Cancer, 2014, 50, 2983-2993.	2.8	56
17	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. International Journal of Cancer, 2020, 147, 285-296.	5.1	56
18	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With <i>RAS</i> and <i>BRAF</i> Mutational Status. JAMA Oncology, 2018, 4, e173695.	7.1	55

#	ARTICLE	IF	CITATIONS
19	Small Bowel Adenocarcinoma. <i>Gastroenterology Clinics of North America</i> , 2016, 45, 447-457.	2.2	48
20	FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4000-4000.	1.6	43
21	Inclusion of Older Patients with Cancer in Clinical Trials: The SAGE Prospective Multicenter Cohort Survey. <i>Oncologist</i> , 2019, 24, e1351-e1359.	3.7	42
22	Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , 2017, 74, 98-108.	2.8	41
23	Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients. <i>Digestive and Liver Disease</i> , 2013, 45, 245-250.	0.9	40
24	COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). <i>Digestive and Liver Disease</i> , 2020, 52, 597-603.	0.9	37
25	Colorectal cancer care in elderly patients: Unsolved issues. <i>Digestive and Liver Disease</i> , 2016, 48, 1112-1118.	0.9	36
26	Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3242-3250.	1.6	35
27	PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)â€”A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3541-3541.	1.6	34
28	Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 154-160.	1.5	33
29	Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. <i>International Journal of Colorectal Disease</i> , 2015, 30, 1305-1310.	2.2	30
30	Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. <i>European Journal of Cancer</i> , 2018, 98, 1-9.	2.8	30
31	FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. <i>European Journal of Cancer</i> , 2019, 115, 97-106.	2.8	29
32	Comparison of Mobility Indices for Predicting Early Death in Older Patients With Cancer: The Physical Frailty in Elderly Cancer Cohort Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 189-196.	3.6	29
33	PRODIGE 34 â€” FFCD 1402 â€” ADAGE. <i>Digestive and Liver Disease</i> , 2016, 48, 206-207.	0.9	26
34	Preferences about information and decision-making among older patients with and without cancer. <i>Age and Ageing</i> , 2017, 46, 665-671.	1.6	24
35	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. <i>EBioMedicine</i> , 2019, 46, 94-104.	6.1	24
36	Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 331-335.	1.0	24

#	ARTICLE	IF	CITATIONS
37	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 4745-4753.	7.0	23
38	Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. <i>British Journal of Cancer</i> , 2018, 119, 424-428.	6.4	22
39	High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patients with colorectal cancer. <i>Journal of Geriatric Oncology</i> , 2014, 5, 384-388.	1.0	21
40	Panel gene profiling of small bowel adenocarcinoma: Results from the <sc>NADEGE</sc> prospective cohort. <i>International Journal of Cancer</i> , 2021, 148, 1731-1742.	5.1	21
41	Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 922-932.	8.1	21
42	Diagnostic performance of gait speed, G8 and G8 modified indices to screen for vulnerability in older cancer patients: the prospective PF-EC cohort study. <i>Oncotarget</i> , 2017, 8, 50393-50402.	1.8	21
43	Safety and efficacy of palliative systemic chemotherapy combined with colorectal self-expandable metallic stents in advanced colorectal cancer: A multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 230-238.	1.5	20
44	Comparison of three lymph node staging schemes for predicting the outcome in patients with small bowel adenocarcinoma: A population-based cohort and international multicentre cohort study. <i>EBioMedicine</i> , 2019, 41, 276-285.	6.1	19
45	Obesity survival paradox in cancer patients: Results from the Physical Frailty in older adult cancer patients (PF-EC) study. <i>Clinical Nutrition</i> , 2019, 38, 2806-2812.	5.0	18
46	Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG). <i>Digestive and Liver Disease</i> , 2020, 52, 493-505.	0.9	17
47	The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcS@Crizotinib Program. <i>Targeted Oncology</i> , 2021, 16, 381-388.	3.6	17
48	Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database. <i>Targeted Oncology</i> , 2017, 12, 805-814.	3.6	16
49	Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1125-1130.	2.2	16
50	Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0230914.	2.5	16
51	Chronological Age and Risk of Chemotherapy Nonfeasibility. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 73-80.	1.3	15
52	Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial. <i>British Journal of Cancer</i> , 2022, 126, 1264-1270.	6.4	15
53	Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). <i>Digestive and Liver Disease</i> , 2018, 50, 408-410.	0.9	14
54	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1153-1161.	2.5	14

#	ARTICLE	IF	CITATIONS
55	Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. <i>Cancer Treatment Reviews</i> , 2021, 97, 102202.	7.7	14
56	FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 "FFCD 0802). <i>Digestive and Liver Disease</i> , 2015, 47, 271-272.	0.9	13
57	Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). <i>Digestive and Liver Disease</i> , 2018, 50, 305-307.	0.9	13
58	Development, validation and clinical impact of a prediction model for 6-month mortality in older cancer patients: the GRADE. <i>Aging</i> , 2020, 12, 4230-4246.	3.1	13
59	Epidemiology, Risk Factors and Diagnosis of Small Bowel Adenocarcinoma. <i>Cancers</i> , 2022, 14, 2268.	3.7	13
60	Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1875626.	3.2	12
61	Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 "REGOLD. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1255-1262.	1.0	12
62	Survival prediction in patients treated by FOLFIRI and bevacizumab for metastatic colorectal cancer (PRODIGE 9) using contrast-enhanced CT texture analysis (SPECTRA).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3601-3601.	1.6	12
63	Adjuvant chemotherapy by FOLFOX for gastric hepatoid adenocarcinoma. <i>Digestive and Liver Disease</i> , 2014, 46, 1135-1136.	0.9	11
64	Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904). <i>Radiotherapy and Oncology</i> , 2019, 140, 84-89.	0.6	11
65	Prognostic value of the PrP ^C -ILK-IDO1 axis in the mesenchymal colorectal cancer subtype. <i>Oncolmmunology</i> , 2021, 10, 1940674.	4.6	11
66	Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). <i>European Journal of Cancer</i> , 2021, 150, 232-239.	2.8	11
67	Impact of tobacco smoking on the patient's outcome after (chemo)radiotherapy for anal cancer. <i>European Journal of Cancer</i> , 2020, 141, 143-151.	2.8	10
68	PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI+Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. <i>Digestive and Liver Disease</i> , 2021, 53, 420-426.	0.9	10
69	High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2782-2788.	4.1	9
70	GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4154-TPS4154.	1.6	9
71	Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2016, 48, 1498-1502.	0.9	8
72	Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). <i>Digestive and Liver Disease</i> , 2021, 53, 306-308.	0.9	8

#	ARTICLE	IF	CITATIONS
73	Biomarker-driven access to crizotinib in ALK, MET, or ROS1 positive (+) malignancies in adults and children: The French National AcSÃ© Program.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2504-2504.	1.6	8
74	Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition. <i>Gut</i> , 2023, 72, 699-709.	12.1	8
75	Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma. <i>Cancers</i> , 2020, 12, 1429.	3.7	7
76	MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 193.	3.7	7
77	Effect of lockdown on digestive system cancer care amongst older patients during the first wave of COVID-19: The CADIGCOVAGE multicentre cohort study. <i>Digestive and Liver Disease</i> , 2022, 54, 10-18.	0.9	7
78	Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4427.	4.1	6
79	Magnetic resonance imaging diffusion-weighted imaging for diagnosis of a gastric hepatoid adenocarcinoma. <i>Digestive and Liver Disease</i> , 2015, 47, 174.	0.9	5
80	Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). <i>Clinical Colorectal Cancer</i> , 2020, 19, 285-290.	2.3	5
81	Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. <i>Journal of the National Cancer Institute</i> , 2021, 113, 496-500.	6.3	5
82	Haemorrhagic shock secondary to a diffuse ulcerative enteritis after Ipilimumab and Nivolumab treatment for metastatic melanoma: a case report. <i>Annals of Palliative Medicine</i> , 2022, 11, 837-842.	1.2	5
83	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. <i>British Journal of Cancer</i> , 2020, 122, 957-962.	6.4	4
84	Inflammatory bowel disease drastically affects the prognosis of patients treated for peritoneal metastases with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 799-804.	1.0	3
85	Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study. <i>European Journal of Cancer</i> , 2019, 123, 92-100.	2.8	3
86	Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer. <i>BMC Medical Research Methodology</i> , 2021, 21, 14.	3.1	3
87	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3515-3515.	1.6	3
88	Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability. <i>Digestive and Liver Disease</i> , 2023, 55, 123-130.	0.9	3
89	Safety of FOLFIRI + Durvalumab +/âˆ™ Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. <i>Biomedicines</i> , 2022, 10, 1211.	3.2	3
90	Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAIN - PRÓDIGE 71 - (FFCD 1710) phase III study. <i>Digestive and Liver Disease</i> , 2020, 52, 1143-1147.	0.9	2

#	ARTICLE	IF	CITATIONS
91	Personalized four-category staging for predicting prognosis in patients with small bowel Adenocarcinoma: an international development and validation study. EBioMedicine, 2020, 60, 102979.	6.1	2
92	Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in FÁ©dÁ©ration Francophone de CancÁ©rologie Digestive (FFCD) trials. European Journal of Cancer, 2021, 153, 40-50.	2.8	2
93	Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbertâ€™s disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study.. Journal of Clinical Oncology, 2013, 31, 3614-3614.	1.6	2
94	Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).. Journal of Clinical Oncology, 2017, 35, 3520-3520.	1.6	2
95	Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).. Journal of Clinical Oncology, 2017, 35, 350-350.	1.6	2
96	Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase II study with panitumumab (FFCD 0904).. Journal of Clinical Oncology, 2019, 37, 3570-3570.	1.6	2
97	Overall Survival and Prognostic Factors among Older Patients with Metastatic Pancreatic Cancer: A Retrospective Analysis Using a Hospital Database. Cancers, 2022, 14, 1105.	3.7	2
98	The Pre-Operative GRADE Score Is Associated with 5-Year Survival among Older Patients with Cancer Undergoing Surgery. Cancers, 2022, 14, 117.	3.7	2
99	The PRODIGE 59-DURIGAST trial: A randomized phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, 4036-4036.	1.6	2
100	Prognostic factors of recurrence of colorectal cancers with microsatellite instability after curative resection: An AGEO retrospective multicenter study.. Journal of Clinical Oncology, 2013, 31, 3536-3536.	1.6	1
101	The activity of crizotinib in chemo-refractory MET-amplified esogastric adenocarcinomas: Results from the AcSÁ©-crizotinib program.. Journal of Clinical Oncology, 2018, 36, 4054-4054.	1.6	1
102	Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.. Journal of Clinical Oncology, 2019, 37, 3550-3550.	1.6	1
103	A decision curve analysis of the clinical usefulness of a two-step frailty assessment strategy in older patients with prostate, breast, colorectal, or lung cancer.. Journal of Clinical Oncology, 2022, 40, 12011-12011.	1.6	1
104	Reply to M. Mo et al. Journal of Clinical Oncology, 2018, 36, 2452-2453.	1.6	0
105	Classic or simplified LV5FU2 regimen: Multivariate analysis from a phase III study in metastatic colorectal cancer in elderly patients.. Journal of Clinical Oncology, 2017, 35, 3550-3550.	1.6	0
106	Impact of the addition of bevacizumab, oxaliplatin or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.. Journal of Clinical Oncology, 2017, 35, e15034-e15034.	1.6	0
107	PRODIGE 34 ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancerâ€™A randomized phase III trial.. Journal of Clinical Oncology, 2017, 35, TPS3628-TPS3628.	1.6	0
108	Colorectal Cancer in Older Adults: Systemic Treatments. , 2018, , 1-11.		0

#	ARTICLE	IF	CITATIONS
109	Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies.. Journal of Clinical Oncology, 2018, 36, 3568-3568.	1.6	0
110	BIONADEGE: Genomic profiling of small bowel adenocarcinoma from the NADEGE prospective cohort.. Journal of Clinical Oncology, 2019, 37, 4140-4140.	1.6	0
111	Implementation of complex perioperative intervention in older patients with cancer (IMPROVED) Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	0
112	Tumors: Colorectal. , 2020, , 1-13.		0
113	Colorectal Cancer in Older Adults: Systemic Treatments. , 2020, , 701-711.		0
114	Tumors: Colorectal. , 2021, , 5222-5234.		0
115	Title is missing!. , 2020, 15, e0230914.		0
116	Title is missing!. , 2020, 15, e0230914.		0
117	Title is missing!. , 2020, 15, e0230914.		0
118	Title is missing!. , 2020, 15, e0230914.		0
119	Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.. Journal of Clinical Oncology, 2022, 40, 3555-3555.	1.6	0